Everything below concerns GW501516. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-19. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
==== Other spiders ==== For a comparison of the toxicity of several kinds of spider bites, see the list of medically significant spider bites Many arachnologists believe that a large number of bites attributed to the brown recluse in the U.S. West Coast are either from other spider species or not spider bites at all. Other spiders in western states that might possibly cause necrotic injuries are the hobo spider, desert recluse spider, and the yellow sac spider. For example, the venom of the hobo spider, a common European species now established in the northwestern United States and southern British Columbia, has been reported to produce similar symptoms as the brown recluse bite when injected into laboratory rabbits. However, the toxicity of hobo spider venom has been called into question: Actual bites (rather than syringe injections) have not been shown to cause necrosis, and no necrotic hobo spider bites have ever been reported where it is native. Numerous other spiders have been associated with necrotic bites in the medical literature. Other recluse species, such as the desert recluse (found in the deserts of southwestern United States), are reported to have caused necrotic bite wounds, though only rarely. The hobo spider and the yellow sac spider have also been reported to cause necrotic bites. However, the bites from these spiders are not known to produce the severe symptoms that can follow from a recluse spider bite, and the level of danger posed by these has been called into question.
NP-40 (also known as Tergitol-type NP-40 and nonyl phenoxypolyethoxylethanol) is a commercially available detergent with CAS Registry Number 9016-45-9. NP-40 is an ethoxylated nonylphenol for non-ionic surfactants and can act as emulsifier and demulsifier agent. NP-40 is often used to break open all membranes within a cell, including the nuclear membrane . To break only the cytoplasmic membrane, other detergents such as digitonin can be used. NP-40 has applications in paper and textile processing, in paints and coatings, and in agrochemical manufacturing. Care should be taken to avoid confusing NP-40 with Nonidet P-40 (octyl phenoxypolyethoxylethanol) which is currently out of production. Nonidet P-40 ("Non-Ionic Detergent") was originally manufactured and trademarked by the Shell Chemical Company, but was phased out of production in the early 2000s. Confusingly, biochemical protocols published between the 1960s and 2000s refer to Shell's Nonidet P-40 as NP-40. Shell's original Nonidet P-40 had a hydrophilic-lipophilic balance (HLB) value of 13.5, as opposed to 12.9 for the currently available IGEPAL CA-630, indicating that the currently available compound is more potent than the compound used in older publications. Indeed, according to a 2017 report, an additional dilution factor of 10 was required for the currently available NP-40 ("Nonidet P-40 substitutes") to match the activity of the previously available, and now discontinued, Shell's Nonidet P-40.
In the late 17th century, the Shroud was placed in the chapel designed for that purpose by architect Guarino Guarini and attached to both the cathedral and the Royal Palace of Turin. It remained there until 1993, when it was moved into the cathedral. Repairs were made to the Shroud in 1694 by Sebastian Valfrè, improving upon the earlier patching by the Poor Clares. Further repairs were made in 1868 by Princess Maria Clotilde of Savoy. The Shroud was first photographed in 1898, during a public exhibition. The Shroud remained the property of the House of Savoy until 1983, when it was bequeathed to the Holy See according to the terms of the will of the former king Umberto II of Italy. A fire, possibly caused by arson, threatened the Shroud on 11 April 1997. In 2002 the Holy See had the Shroud restored. The cloth backing and thirty patches were removed, making it possible to photograph and scan the reverse side of the cloth, which had been hidden from view. A faint part-image of the body was found on the back of the Shroud in 2004. The Shroud was placed back on public display (the 18th time in its history) in Turin from 10 April to 23 May 2010; and according to Church officials, more than 2 million visitors came to see it. On Holy Saturday (30 March) 2013, images of the Shroud were streamed on various websites as well as on television for the first time in 40 years.
Nuclear terrorism by non-state organizations or actors (even individuals) is a largely unknown and understudied factor in nuclear deterrence thinking, as states possessing nuclear weapons are susceptible to retaliation in kind, while sub- or trans-state actors may be less so. The collapse of the Soviet Union has given rise to the possibility that former Soviet nuclear weapons might become available on the black market (so-called 'loose nukes'). A number of other concerns have been expressed about the security of nuclear weapons in newer nuclear powers with relatively less stable governments, such as Pakistan, but in each case, the fears have been addressed to some extent by statements and evidence provided by those nations, as well as cooperative programs between nations. Worry remains, however, in many circles that a relative decrease in the security of nuclear weapons has emerged in recent years, and that terrorists or others may attempt to exert control over (or use) nuclear weapons, militarily applicable technology, or nuclear materials and fuel. Another possible nuclear terrorism threat are devices designed to disperse radioactive materials over a large area using conventional explosives, called dirty bombs. The detonation of a "dirty bomb" would not cause a nuclear explosion, nor would it release enough radiation to kill or injure a large number of people. However, it could cause severe disruption and require potentially very costly decontamination procedures and increased spending on security measures.
== Further reading == Reilly, Bernard F. (1988). "The Reconstitution of León-Castilla". The Kingdom of León-Castilla under King Alfonso VI, 1065–1109. Princeton: Princeton University Press. pp. 3–13. ... the hilltop, fortress city of Coimbra fell, after a six-month siege, on July 25, 1064.
Sources: en.wikipedia.org
Aminoacyl-tRNA synthetase enzymes consume ATP in the attachment tRNA to amino acids, forming aminoacyl-tRNA complexes. Aminoacyl transferase binds AMP-amino acid to tRNA. The coupling reaction proceeds in two steps: aa + ATP ⟶ aa-AMP + PPi aa-AMP + tRNA ⟶ aa-tRNA + AMP The amino acid is coupled to the penultimate nucleotide at the 3′-end of the tRNA (the A in the sequence CCA) via an ester bond (roll over in illustration). Transporting chemicals out of a cell against a gradient is often associated with ATP hydrolysis. Transport is mediated by ATP binding cassette transporters. The human genome encodes 48 ABC transporters, that are used for exporting drugs, lipids, and other compounds.
CDs and DVDs have a protective film which must be stripped to reveal the gold reflective film or polycarbonate (PC) base. The surface of the disk can be activated to reveal the metal layer which allows compounds to bind to it. Compounds such as UV/ozone or an oxygen plasma treatment can be used to activate the disk to produce a hydrophilic surface with densely packed carboxylic acid groups. As one-off microassay can be printed onto the activated disks using a noncontact printer to dispel nanoliter quantities of coating conjugates onto the disk. Proteins or antibodies acting as probe molecules can then covalently bind to the disk surface and can be incubated. A polydimethylsiloxane (PDMS) channel plate can also be used to immobilize the probes in a line array. The plate is removed, and the process is repeated with another plate to deliver analyte samples in a line array perpendicular to the probe array. The probe and analyte samples can bind or hybridize at the intersections of the arrays to create rectangular hybridization sites. The disk is washed, rinsed, and dried prior to reading. This process can be done manually or automated; in theory discs with pre-made assays could be manufactured and sold en masse.
Tuberculin, known in its modern form as purified protein derivative (PPD), is a combination of proteins that are used in the diagnosis of tuberculosis by injection into the skin. Common side effects include redness, itchiness (pruritus), and pain at the site of injection. Allergic reactions may occasionally occur. Use is safe in pregnancy. The original tuberculin, a glycerin extract of Mycobacterium tuberculosis, was discovered in 1890 by Robert Koch. Koch, best known for his work on the etiology (cause, origin) of tuberculosis (TB), laid down various rigorous guidelines that aided the establishment between a pathogen and the specific disease that followed that were later named Koch's postulates. Although he initially believed it would cure tuberculosis, this was later disproved. PPD was invented in 1934 by Florence B. Seibert, greatly improving the reliability of the skin test over Koch's extract. PPD is on the World Health Organization's List of Essential Medicines.
Botulinum neurotoxins (BoNTs) are the causative agents of the deadly food poisoning disease botulism, and could pose a major biological warfare threat due to their extreme toxicity and ease of production. They also serve as powerful tools to treat an ever expanding list of medical conditions that benefit from its paralytic properties, an example drug with BoNTs as the active ingredient is Botox. TBotulinum neurotoxins (BoNTs) are protein neurotoxins that are produced by the bacteria Clostridium. BoNTs are now largely being studied due to their ability to aid in chronic inflammatory diseases such as acne, multiple sclerosis, and for cosmetic purposes.
40. Pain Physician. 2026 Sep;29(6):E751. Comment on "Cervical Erector Spinae Plane Block vs. Epidural Steroid Injection for Cervical Radicular Pain: A Clinical Trial". Sacaklidir GY(1), Sacaklidir R(2). Author information: (1)Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey. (2)Sisli Hamidiye Etfal Training and Research Hospital, Department of Physical Medicine and Rehabilitation, Pain Management Section, Istanbul, Turkey.
Sources: en.wikipedia.org
== Associated disorders == Collagen-related diseases most commonly arise from genetic defects or nutritional deficiencies that affect the biosynthesis, assembly, posttranslational modification, secretion, or other processes involved in normal collagen production.
In July 2008, the whole site was rebranded under the Edge title, as that was the senior of the two brands. In May 2014 it was reported that Future intended to close the websites of Edge, Computer and Video Games and their other videogame publications; in December 2014, it was confirmed that the C&VG website would close and its content would instead be published at GamesRadar, and in January 2015, it was announced that the same would happen to the Edge website. Between 2015 and 2018, Edge articles were occasionally republished on Kotaku UK. Edge has been redesigned three times since the magazine launched. The first redesign occurred in 1999; the second in 2004; and the third in 2011. The first redesign altered the magazine's dimensions to be wider than the original shape. The latest design changes the magazine's physical dimensions for the second time, and introduces a higher quality of paper stock than was previously used.
=== Alkaline corneal burns === Hitoshi et al. showed that trimebutine can inhibit inflammation in corneal burns caused by alkali. This protective activity is thought to be mediated by high-mobility group box 1-receptor inhibitor, which causes decreased macrophage and neutrophil infiltration.
=== Films === Munim made her debut in Hindi films with filmmaker Dev Anand's Des Pardes. Her other films with Dev Anand include Lootmaar, and Man Pasand. She was cast opposite Amol Palekar in Basu Chatterjee's Baaton Baaton Mein. Her notable films with Rishi Kapoor include Karz, and Yeh Vaada Raha.She starred with actor Rajesh Khanna in many films including Fiffty Fiffty, Souten, Bewafai, Suraag, Insaaf Main Karoonga, Rajput, Aakhir Kyon?, Paapi Pet Ka Sawaal Hai, Alag Alag, and Adhikar. She also starred in hits like Bhagwaan Dada with Rajinikanth and Yudh with Jackie Shroff. Her last film was Jigarwala, released in 1991. In an interview with Simi Garewal, Munim said: "Sometimes I feel [that I left films too soon] too, but then I felt that there was a lot more to the world that I wanted to explore and experience, and not just stick to movies. I decided to quit. I never regretted it. I never wanted to go back, ever."
=== Hydration and dehydration reactions === With judicious heating, gypsum converts to the partially dehydrated mineral called bassanite or plaster of Paris. This material has the formula CaSO4·(nH2O), where 0.5 ≤ n ≤ 0.8. Temperatures between 100 and 150 °C (212–302 °F) are required to drive off the water within its structure. The details of the temperature and time depend on ambient humidity. Temperatures as high as 170 °C (338 °F) are used in industrial calcination, but at these temperatures γ-anhydrite begins to form. The heat energy delivered to the gypsum at this time (the heat of hydration) tends to go into driving off water (as water vapor) rather than increasing the temperature of the mineral, which rises slowly until the water is gone, then increases more rapidly. The equation for the partial dehydration is:
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.